{"created":"2023-05-15T09:17:35.443337+00:00","id":435,"links":{},"metadata":{"_buckets":{"deposit":"58e9a69c-297f-4f95-95de-e0c05ffc9e31"},"_deposit":{"created_by":15,"id":"435","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"435"},"status":"published"},"_oai":{"id":"oai:iuhw.repo.nii.ac.jp:00000435","sets":["2:103"]},"author_link":["1204","116","203","610","165","1148","164","1203"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-10-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"67","bibliographicPageStart":"58","bibliographicVolumeNumber":"18","bibliographic_titles":[{"bibliographic_title":"国際医療福祉大学学会誌"},{"bibliographic_title":"Journal of the International University of Health and Welfare","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"S-1 + cisplatin combination therapy and S-1 single-agent therapy are widely administered as primary chemotherapies for progressive stomach cancer. Although the SPIRITS trial reported a prolongation of survival for the combination therapy, an increase in the medical costs of the combination therapy as well as the higher number of adverse events in the combination therapy compared to the single agent therapy was expected. To investigate the comparative cost-benefit status of these two therapies, we performed a cost–utility analysis from the health care payer's perspective. We collected cost data from patients with stomach cancer in one hospital. The utility was measured using the time trade-off method. Thereafter, we estimated the expected cost and quality-adjusted life years (QALYs) for five years using a Markov model. The cost-effectiveness ratio was 4,980,000 yen/QALY for the combination therapy and 7,623,000 yen/QALY for the single-agent therapy. Compared with the single-agent therapy, the incremental cost-effectiveness ratio of the combination therapy was only 620,000 yen/QALY. Therefore, considering the relative cost-benefit of chemotherapy, the combination therapy for progressive stomach cancer was recommended.","subitem_description_type":"Abstract"}]},"item_10001_description_6":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"進行胃がんに対する一次化学療法として,S-1+シスプラチン併用療法やS-1 単剤療法が広く行われている.併用療法はSPIRITS 試験により延命効果が認められたが,一方で,単剤療法より,有害事象の増加とともに費用の増加も予想された.これらの影響を含めた両治療法の評価を行うため,保健医療費支払者の立場から費用効用分析を行った.A 病院において胃がんの治療として各治療法を施行された患者から費用データを収集,効用値は時間得失法を用いて測定を行い,マルコフモデルを用いた5 年間のシミュレーションを行った.平均費用効果比は,併用療法で498.0 万円/QALY,単剤療法で762.3 万円/QALY であり,単剤療法を基準とした場合の併用療法の増分費用効果比は62.0 万円/QALY と算出された.併用療法は単剤療法よりも医療費が高くなるものの費用対効果の点では許容される範囲にあることから,患者が希望する場合には併用療法を積極的に実施することが適切と考えられた.","subitem_description_type":"Other"}]},"item_10001_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{}],"names":[{"name":"Nakamura, Mari"}]},{"nameIdentifiers":[{}],"names":[{"name":"Shimizu, Takaaki"}]},{"nameIdentifiers":[{}],"names":[{"name":"Ikeda, Shunya"}]},{"nameIdentifiers":[{}],"names":[{"name":"Takeda, Hiroshi"}]}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"国際医療福祉大学学会"}]},"item_10001_radio_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_radio_item":"publisher"}]},"item_10001_relation_12":{"attribute_name":"NII論文ID（NAID）","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"110009625572"}]}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"CiNii"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://ci.nii.ac.jp/naid/110009625572","subitem_relation_type_select":"URI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID（NCID）","attribute_value_mlt":[{"subitem_source_identifier":"AA12537130","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"21863652","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"中村, 真理"},{"creatorName":"ナカムラ, マリ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"清水, 隆明"},{"creatorName":"シミズ, タカアキ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"池田, 俊也"},{"creatorName":"イケダ, シュンヤ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"武田, 弘志"},{"creatorName":"タケダ, ヒロシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2013-12-03"}],"displaytype":"simple","filename":"18_2(58-67p).pdf","filesize":[{"value":"1.5 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"本文(PDF)","url":"https://iuhw.repo.nii.ac.jp/record/435/files/18_2(58-67p).pdf"},"version_id":"ab1e3ca9-d862-489c-998c-3ccbbff34536"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"胃がん","subitem_subject_scheme":"Other"},{"subitem_subject":"化学療法","subitem_subject_scheme":"Other"},{"subitem_subject":"費用対効果","subitem_subject_scheme":"Other"},{"subitem_subject":"効用値","subitem_subject_scheme":"Other"},{"subitem_subject":"質調整生存年","subitem_subject_scheme":"Other"},{"subitem_subject":"Stomach cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cost-effectiveness","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Utility","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Quality-adjusted Life Years (QALYs)","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"進行胃がんに対する化学療法の費用対効果に関する研究","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"進行胃がんに対する化学療法の費用対効果に関する研究"},{"subitem_title":"Cost-effectiveness of chemotherapy for the progressive stomach cancer","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"15","path":["103"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-12-03"},"publish_date":"2013-12-03","publish_status":"0","recid":"435","relation_version_is_last":true,"title":["進行胃がんに対する化学療法の費用対効果に関する研究"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2023-06-21T10:45:20.955640+00:00"}